市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Lantern Pharma Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-1.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.50 |
|
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.10% |
| 机构持股比例 | 21.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Empery Asset Management, Lp | 30 Jun 2026 | 842,669 |
| Cm Management, Llc | 30 Jun 2026 | 500,000 |
| Bios Capital Management, Lp | 30 Jun 2026 | 249,397 |
| Westside Investment Management, Inc. | 30 Jun 2026 | 47,850 |
| Quadrature Capital Ltd | 30 Jun 2026 | 39,593 |
| Newedge Advisors, Llc | 30 Jun 2026 | 27,049 |
| Horizon Kinetics Asset Management Llc | 30 Jun 2026 | 25,164 |
| Davenport & Co Llc | 30 Jun 2026 | 23,814 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合